Category: Zacks Small Cap Research

1686970717298700 / 972 POSTS
By Steven Ralston, CFATSX:WML.VREAD THE FULL WML.V RESEARCH REPORTCEO Wealth Minerals Hosts Conference CallOn November 7, 2018, Henk Van Alphen, CEO of Wealth Minerals (TSX:WML.V), conducted a conference call to update the investment community on the ...
By David Bautz, PhDNYSE:OGENREAD THE FULL OGEN RESEARCH REPORTBusiness UpdateAdditional Clinical Trial Sites Open in Europe for Phase 2 Trial of AG013Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2, double blind, placebo controlled clin ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTFinancial UpdateOn Nov. 9, 2018, Soligenix (NASDAQ:SNGX) announced financial results for the third quarter of 2018. The company reported revenues of $1.4 million in the third quarter of ...
By David Bautz, PhDNASDAQ:TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness UpdateNew Phase 3 Trial for TNX-102 SL to Initiate in 1Q19On October 31, 2018, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that the company will be initiating a ...
By Steven Ralston, CFANASDAQ:MNGAREAD THE FULL RESEARCH REPORT HEREMagneGas Expanding in Domestic Industrial Gas Business & Pursuing European GrantsMagneGas Applied Technology Solutions (NASDAQ:MNGA) produces, sells and distributes MagneGas2®, a ...
By Brian Marckx, CFAQ3 Financial Results and Operational UpdateNASDAQ:DRRXREAD THE FULL RESEARCH REPORT HERELast week Durect (NASDAQ:DRRX) reported financial results for their third quarter ending September 30th and provided a business update.  Relat ...
By Lisa ThompsonNASDAQ:CIDMREAD THE FULL RESEARCH REPORT HERERevenues for the quarter ending September 30, 2018 came in significantly above expectations at $13.7 million versus $16.3 million a year ago, declining 16%. $7.5 million came from the legac ...
By David Bautz, PhDNASDAQ:ORMPREAD THE FULL RESEARCH REPORT HEREBusiness UpdateOramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a biotechnology company with a proprietary oral protein delivery platform technology. The lead development candidate is ORMD-0 ...
By John Vandermosten, CFANASDAQ:ATXIAvenue Therapeutics (NASDAQ:ATXI) announced an acquisition agreement with InvaGen Pharmaceuticals to acquire a 33.3% stake in the company for $35 million to be followed by a second stage closing in 2021 which will ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdatePhase 2 Data for VK2809 Presented at AASLDOn November 12, 2018, Viking Therapeutics, Inc. (NASDAQ:VKTX) presented results from the Phase 2 trial of VK2809, the company’s t ...
1686970717298700 / 972 POSTS